Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Targeting PCSK9 reduces cancer cell stemness and enhances antitumor immunity in head and neck cancer
Qi‐Chao Yang, Shuo Wang, Yuan‐Tong Liu, et al.
iScience (2023) Vol. 26, Iss. 6, pp. 106916-106916
Open Access | Times Cited: 14

Showing 14 citing articles:

Targeting proprotein convertase subtilisin/kexin type 9 (PCSK9): from bench to bedside
Xuhui Bao, Yongjun Liang, Hanman Chang, et al.
Signal Transduction and Targeted Therapy (2024) Vol. 9, Iss. 1
Open Access | Times Cited: 56
Potential use of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibition and prevention method in viral infection
Khursheed Muzammil, Mohammad Hosseini Hooshiar, Shirin Varmazyar, et al.
Microbial Cell Factories (2024) Vol. 23, Iss. 1
Open Access | Times Cited: 14
Glycolysis-cholesterol metabolic axis in immuno-oncology microenvironment: emerging role in immune cells and immunosuppressive signaling
Jing Jin, Qijie Zhao, Zhigong Wei, et al.
Cell & Bioscience (2023) Vol. 13, Iss. 1
Open Access | Times Cited: 12
The multifaceted role of PCSK9 in cancer pathogenesis, tumor immunity, and immunotherapy
Chou‐Yi Hsu, Mustafa Nasrat Abdulrahim, Mohammed Ahmed Mustafa, et al.
Medical Oncology (2024) Vol. 41, Iss. 8
Closed Access | Times Cited: 4
Targeting PCSK9, through an innovative cVLP-based vaccine, enhanced the therapeutic activity of a cVLP-HER2 vaccine in a preclinical model of HER2-positive mammary carcinoma
Laura Scalambra, Francesca Ruzzi, Olga Maria Pittino, et al.
Journal of Translational Medicine (2025) Vol. 23, Iss. 1
Open Access
Prognostic implications of PCSK9 expression in HER2-positive breast cancer
Zongwen Wu, D. Wu, Chengsheng Huang, et al.
ONCOLOGIE (2025)
Closed Access
The role of lipids and lipids lowering drugs in human papillomavirus (HPV) and HPV-associated cancers
Ehsan Shabani, Aida Hasanzadi, Omer Qutaiba B. Allela, et al.
Infectious Agents and Cancer (2025) Vol. 20, Iss. 1
Open Access
Effects of PCSK9 inhibitors on cancer, diabetes, and cardiovascular diseases
Mojgan Nejabat, Farzin Hadizadeh, Wael Almahmeed, et al.
Drug Discovery Today (2025), pp. 104316-104316
Closed Access
Targeting cholesterol metabolism: a promising therapy strategy for cancer
Chun-Lan Dai, Zhixin Qiu, Anqi Wang, et al.
Acta Pharmacologica Sinica (2025)
Closed Access
Serum PCSK9 is a novel serological biomarker for the diagnosis and prognosis of pancreatic cancer
Ying Xu, Yongfeng Xu, Yang Yang, et al.
PeerJ (2024) Vol. 12, pp. e18018-e18018
Open Access | Times Cited: 1
Head and Neck Cancer and Lipid Levels: New Horizons in Pathophysiology and Treatments
Aysel Kalayci, Deniz Ağırbaşlı, Mehmet Ağırbaşlı
Springer eBooks (2024)
Closed Access
An innovative gene expression modulating strategy by converting nucleic acids into HNC therapeutics using carrier-free nanoparticles
Heyuan Liu, Yinong Huang, Zongfang Li, et al.
Frontiers in Immunology (2024) Vol. 14
Open Access
Prognostic Value of PCSK9 Levels in Premenopausal Women at Risk of Breast Cancer—Evidence from a 17-Year Follow-Up Study
Massimiliano Ruscica, Chiara Macchi, Sara Gandini, et al.
Cancers (2024) Vol. 16, Iss. 7, pp. 1411-1411
Open Access
Association between higher glucose levels and reduced survival in patients with non-small cell lung cancer treated with immune checkpoint inhibitors
Soravis Osataphan, Muhammad Awidi, Yu Jen Jan, et al.
Lung Cancer (2024) Vol. 198, pp. 108023-108023
Closed Access
Page 1

Scroll to top